ORLANDO — In this video from the American Academy of Ophthalmology meeting, Esther M. Bowie, MD, discusses what is “new and exciting” in wet age-related macular degeneration.
Tyrosine kinase inhibitors being investigated for wet AMD include EYP-1901 (vorolanib intravitreal insert, EyePoint Pharmaceuticals) and OTX-TKI, also known as Axpaxli (axitinib intravitreal implant, Ocular Therapeutix). Current studies of the intravitreal implants demonstrated preliminary results similar to Eylea (aflibercept 2 mg, Regeneron), Bowie said.
In addition, gene therapy is currently under